Monitoring nanoparticle-treated hepatocarcinoma cells for apoptosis.
This chapter describes a method for monitoring nanoparticle treated human hepatocarcinoma cells (Hep G2) for apoptosis. The protocol utilizes a fluorescent method to determine the degree of caspase-3 activation.
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD, USA.
Timothy M
TM
Potter
Stephan T
ST
Stern
D017209:Apoptosis / Q000187:drug effects*; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D053148:Caspase 3 / Q000378:metabolism; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D003374:Coumarins / Q000032:analysis / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D053758:Nanoparticles / Q000633:toxicity*; D009842:Oligopeptides / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013379:Substrate Specificity
D003374:Coumarins; D009842:Oligopeptides; C115495:aspartyl-glutamyl-valyl-aspartyl-7-amino-4-trifluoromethylcoumarin; C055467:7-amino-4-trifluoromethylcoumarin; D053148:Caspase 3